[go: up one dir, main page]

AU2001280161A1 - C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes - Google Patents

C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes

Info

Publication number
AU2001280161A1
AU2001280161A1 AU2001280161A AU8016101A AU2001280161A1 AU 2001280161 A1 AU2001280161 A1 AU 2001280161A1 AU 2001280161 A AU2001280161 A AU 2001280161A AU 8016101 A AU8016101 A AU 8016101A AU 2001280161 A1 AU2001280161 A1 AU 2001280161A1
Authority
AU
Australia
Prior art keywords
erythrocytes
medicinal compositions
mpl ligand
containing medicinal
increasing platelets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280161A
Inventor
Masami Bessho
Norio Komatsu
Hideaki Mizoguchi
Akio Urabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirin Brewery Co Ltd
Original Assignee
Kirin Brewery Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery Co Ltd filed Critical Kirin Brewery Co Ltd
Publication of AU2001280161A1 publication Critical patent/AU2001280161A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001280161A 2000-08-24 2001-08-24 C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes Abandoned AU2001280161A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-254473 2000-08-24
JP2000254473 2000-08-24
PCT/JP2001/007283 WO2002015926A1 (en) 2000-08-24 2001-08-24 c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES

Publications (1)

Publication Number Publication Date
AU2001280161A1 true AU2001280161A1 (en) 2002-03-04

Family

ID=18743415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280161A Abandoned AU2001280161A1 (en) 2000-08-24 2001-08-24 C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes

Country Status (2)

Country Link
AU (1) AU2001280161A1 (en)
WO (1) WO2002015926A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP2211855A4 (en) * 2007-10-09 2011-12-07 Univ Pennsylvania THROMBOPOIETIN RECEPTOR AGONIST (TPORA) DESTROYING THE CELLS OF ACUTE HUMAN MYELOID LEUKEMIA
EA201790439A1 (en) 2014-08-22 2017-07-31 Селджин Корпорейшн METHODS OF TREATING MULTIPLE MYELOMA WITH THE USE OF IMMUNOMODULATING COMPOUNDS IN COMBINATION WITH ANTIBODIES
US10001483B2 (en) 2015-06-26 2018-06-19 Celgene Corporation Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
EP3881856B1 (en) * 2018-10-26 2024-08-07 Kyowa Kirin Co., Ltd. Pharmaceutical composition for treating aplastic anemia
US20240010736A1 (en) * 2020-11-24 2024-01-11 Daegu Gyeongbuk Institute Of Science And Technology Novel anti-c-mpl antibody and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316254B1 (en) * 1994-02-14 2001-11-13 University Of Washington Methods for stimulating erythropoiesis using hematopoietic proteins
NZ281482A (en) * 1994-02-14 2000-09-29 Univ Washington The stimulation of erythropoiesis using thrombopoietin and erythropoietin
EP0690127B1 (en) * 1994-03-31 1998-08-05 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
CA2212006A1 (en) * 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
CN1230993A (en) * 1996-08-13 1999-10-06 津莫吉尼蒂克斯公司 Expression vector, cell and method for preparing thrombopoietin polypeptide
WO1998014476A1 (en) * 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
AU3538799A (en) * 1998-04-30 1999-11-23 Kirin Brewery Company, Limited Human thrombopoietin mutants

Also Published As

Publication number Publication date
WO2002015926A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU4866001A (en) Alprazolam inclusion complexes and pharmaceutical compositions thereof
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2002306269A1 (en) N-arylphenylacetamide derivatives and pharmaceutical composition containing the same
EP1329456A4 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL158523A0 (en) Epothilone derivatives and pharmaceutical compositions containing the same
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
HUP0400887A3 (en) Glycopeptide derivatives and pharmaceutical compositions containing the same
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
IL152846A0 (en) Pyridazinone derivatives and pharmaceutical compositions containing the same
AU2002253219A1 (en) Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same
IL156813A0 (en) Imidazolyl derivatives and pharmaceutical compositions containing the same
AU1800600A (en) Ume extract having medicinal effects and compositions containing the same
AU2001290239A1 (en) Medicinal composition
AU2001280161A1 (en) C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
AU2002360117A1 (en) Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same
AU3192500A (en) Substituted proline derivatives and medicinal compositions containing the same
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same